Literature DB >> 25921936

Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009).

W Huang1, R J Goldberg2, A T Cohen3, F A Anderson4, C I Kiefe2, J M Gore5, F A Spencer6.   

Abstract

INTRODUCTION: Contemporary trends in health-care delivery are shifting the management of venous thromboembolism (VTE) events (deep vein thrombosis [DVT] and/or pulmonary embolism [PE]) from the hospital to the community, which may have implications for its prevention, treatment, and outcomes.
MATERIALS AND METHODS: Population-based surveillance study monitoring trends in clinical epidemiology among residents of the Worcester, Massachusetts, metropolitan statistical area (WMSA) diagnosed with an acute VTE in all 12 WMSA hospitals. Patients were followed for up to 3 years after their index event. Total of 2334 WMSA residents diagnosed with first-time community-presenting VTE (occurring in an ambulatory setting or diagnosed within 24 hours of hospitalization) from 1999 through 2009.
RESULTS: While PE patients were consistently admitted to the hospital for treatment over time, the proportion diagnosed with DVT-alone admitted to the hospital decreased from 67% in 1999 to 37% in 2009 (p value for trend <0.001). Among hospitalized patients, the mean length of stay decreased from 5.6 to 4.8 days (p value for trend <0.001). Between 1999 and 2009, treatment of VTE shifted from warfarin and unfractionated heparin towards use of low-molecular-weight heparins and newer anticoagulants; also, 3-year cumulative event rates decreased for all-cause mortality (41-26%), major bleeding (12-6%), and recurrent VTE (17-9%).
CONCLUSIONS: A decade of change in VTE management was accompanied by improved long-term outcomes. However, rates of adverse events remained fairly high in our population-based surveillance study, implying that new risk-assessment tools to identify individuals at increased risk for developing major adverse outcomes over the long term are needed.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adverse events; Risk assessment; Venous thromboembolism

Mesh:

Substances:

Year:  2015        PMID: 25921936      PMCID: PMC4416217          DOI: 10.1016/j.thromres.2015.04.007

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  36 in total

1.  Upper extremity deep vein thrombosis: a community-based perspective.

Authors:  Frederick A Spencer; Cathy Emery; Darleen Lessard; Robert J Goldberg
Journal:  Am J Med       Date:  2007-08       Impact factor: 4.965

2.  Upper vs. lower extremity deep vein thrombosis: outcome definitions of venous thromboembolism for clinical predictor rules or risk factor analyses in hospitalized patients.

Authors:  A C Spyropoulos
Journal:  J Thromb Haemost       Date:  2009-06       Impact factor: 5.824

3.  Reflecting on eight editions of the American College of Chest Physicians antithrombotic guidelines.

Authors:  Jack Hirsh; Gordon Guyatt; Sandra Zelman Lewis
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

4.  The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism.

Authors:  Frederick A Spencer; Cathy Emery; Darleen Lessard; Frederick Anderson; Sri Emani; Jayashri Aragam; Richard C Becker; Robert J Goldberg
Journal:  J Gen Intern Med       Date:  2006-07       Impact factor: 5.128

Review 5.  Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.

Authors:  Marc Carrier; Grégoire Le Gal; Philip S Wells; Marc A Rodger
Journal:  Ann Intern Med       Date:  2010-05-04       Impact factor: 25.391

6.  Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop.

Authors:  Gary E Raskob; Roy Silverstein; Dale W Bratzler; John A Heit; Richard H White
Journal:  Am J Prev Med       Date:  2010-04       Impact factor: 5.043

7.  The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.

Authors:  Paolo Prandoni; Franco Noventa; Angelo Ghirarduzzi; Vittorio Pengo; Enrico Bernardi; Raffaele Pesavento; Matteo Iotti; Daniela Tormene; Paolo Simioni; Antonio Pagnan
Journal:  Haematologica       Date:  2007-02       Impact factor: 9.941

8.  Venous thromboembolism in the outpatient setting.

Authors:  Frederick A Spencer; Darleen Lessard; Cathy Emery; George Reed; Robert J Goldberg
Journal:  Arch Intern Med       Date:  2007-07-23

9.  Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.

Authors:  Alexander T Cohen; Victor F Tapson; Jean-Francois Bergmann; Samuel Z Goldhaber; Ajay K Kakkar; Bruno Deslandes; Wei Huang; Maksim Zayaruzny; Leigh Emery; Frederick A Anderson
Journal:  Lancet       Date:  2008-02-02       Impact factor: 79.321

10.  Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample.

Authors:  Brian Park; Louis Messina; Phong Dargon; Wei Huang; Rocco Ciocca; Frederick A Anderson
Journal:  Chest       Date:  2009-06-12       Impact factor: 9.410

View more
  6 in total

Review 1.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

2.  Treatment and Outcomes of Acute Pulmonary Embolism and Deep Venous Thrombosis: The CVRN VTE Study.

Authors:  Margaret C Fang; Dongjie Fan; Sue Hee Sung; Daniel M Witt; John R Schmelzer; Marc S Williams; Steven H Yale; Christine Baumgartner; Alan S Go
Journal:  Am J Med       Date:  2019-06-25       Impact factor: 4.965

3.  National and Regional Trends in Deep Vein Thrombosis Hospitalization Rates, Discharge Disposition, and Outcomes for Medicare Beneficiaries.

Authors:  Karl E Minges; Behnood Bikdeli; Yun Wang; Robert R Attaran; Harlan M Krumholz
Journal:  Am J Med       Date:  2018-06-23       Impact factor: 4.965

4.  IQCA-TAVV: To explore the effect of P-selectin, GPIIb/IIIa, IL-2, IL-6 and IL-8 on deep venous thrombosis.

Authors:  Jianhui Wu; Haimei Zhu; Guodong Yang; Yuji Wang; Yaonan Wang; Shurui Zhao; Ming Zhao; Shiqi Peng
Journal:  Oncotarget       Date:  2017-08-24

5.  Discretionary Thrombophilia Test Acquisition and Outcomes in Patients With Venous Thromboembolism in a Real-World Clinical Setting.

Authors:  Patrick M Kozak; Meng Xu; Eric Farber-Eger; David Gailani; Quinn S Wells; Joshua A Beckman
Journal:  J Am Heart Assoc       Date:  2019-11-07       Impact factor: 5.501

6.  Incidence and Predictors of Recurrence and Mortality Following First Venous Thromboembolism Among the Saudi Population: Single-Center Cohort Study.

Authors:  Fahad A S AlEidan; Reem K AlManea; Alyah T AlMoneef; Nada A Shalash; Norah A AlRajhi; Sarah F AlMousa; Abdulrahman Al Raizah; Khadega A Abuelgasim
Journal:  Int J Gen Med       Date:  2022-09-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.